Volitionrx Ltd Total Liabilities
Volitionrx Ltd total liabilities. Based on the latest financial reports, Volitionrx Ltd (VNRX) has total liabilities worth $42.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Volitionrx Ltd (VNRX) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Volitionrx Ltd (2004–2025)
Total liabilities of Volitionrx Ltd from 2004 to 2025. This chart illustrates how Volitionrx Ltd's total liabilities have evolved over time, based on quarterly financial data.
Volitionrx Ltd Competitors by Total Liabilities
The table below lists competitors of Volitionrx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SSP Group PLC
LSE:SSPG
|
UK | GBX3.16 Billion |
|
Brill Shoe Industries Ltd
TA:BRIL
|
Israel | ILA419.78 Million |
|
TEAM PLC
F:1WQ
|
Germany | €5.29 Million |
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
USA | $23.02 Million |
|
Stern Groep N.V.
AS:PBH
|
Netherlands | €822.00K |
|
DAIHAN Scientific Co. Ltd
KQ:131220
|
Korea | ₩13.84 Billion |
|
KebNi AB (publ)
ST:KEBNI-B
|
Sweden | Skr37.29 Million |
|
Libet S.A.
WAR:LBT
|
Poland | zł22.31 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Volitionrx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VNRX total asset value.
Liquidity & Leverage Metrics
Volitionrx Ltd Total Liabilities Ratios Explained
Volitionrx Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Volitionrx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Volitionrx Ltd (2004–2025)
The table below shows the annual total liabilities of Volitionrx Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.49 Million | +19.68% |
| 2024-12-31 | $35.51 Million | -3.15% |
| 2023-12-31 | $36.66 Million | +71.15% |
| 2022-12-31 | $21.42 Million | +119.30% |
| 2021-12-31 | $9.77 Million | -0.90% |
| 2020-12-31 | $9.86 Million | +38.97% |
| 2019-12-31 | $7.09 Million | +32.61% |
| 2018-12-31 | $5.35 Million | +14.61% |
| 2017-12-31 | $4.67 Million | +31.17% |
| 2016-12-31 | $3.56 Million | +113.35% |
| 2015-12-31 | $1.67 Million | -45.59% |
| 2014-12-31 | $3.06 Million | +120.48% |
| 2013-12-31 | $1.39 Million | +0.51% |
| 2012-12-31 | $1.38 Million | +19.60% |
| 2011-12-31 | $1.16 Million | +907.47% |
| 2010-12-31 | $114.77K | +3.42% |
| 2009-12-31 | $110.98K | +11.83% |
| 2008-12-31 | $99.24K | +20.06% |
| 2007-12-31 | $82.66K | +41.34% |
| 2006-12-31 | $58.48K | -19.93% |
| 2005-12-31 | $73.04K | +13.95% |
| 2004-12-31 | $64.10K | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more